H

Hana Pharm Co Ltd
KRX:293480

Watchlist Manager
Hana Pharm Co Ltd
KRX:293480
Watchlist
Price: 11 010 KRW 0.82% Market Closed
Market Cap: 190.5B KRW
Have any thoughts about
Hana Pharm Co Ltd?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

7.1
Current
7
Median
13.5
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
7.1
=
Enterprise Value
212.2B KRW
/
EBITDA
29.8B KRW
All Countries
Close
Market Cap EV/EBITDA
KR
Hana Pharm Co Ltd
KRX:293480
190.5B KRW 7.1
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 459 134.4
US
Eli Lilly and Co
NYSE:LLY
729.3B USD 46.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK 20.7
US
Johnson & Johnson
NYSE:JNJ
347.8B USD 11.5
US
Merck & Co Inc
NYSE:MRK
248.3B USD 10.3
CH
Roche Holding AG
SIX:ROG
199.4B CHF 9.8
UK
AstraZeneca PLC
LSE:AZN
161.4B GBP 169.4
CH
Novartis AG
SIX:NOVN
170.9B CHF 9.4
US
Pfizer Inc
NYSE:PFE
149.4B USD 10.5
EBITDA Growth EV/EBITDA to Growth
KR
H
Hana Pharm Co Ltd
KRX:293480
Average EV/EBITDA: 414.2
7.1
16%
0.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.9
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.7
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.3
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
6.1
2-Years Forward
EV/EBITDA
5.7
3-Years Forward
EV/EBITDA
5.3

See Also

Discover More